Form 4: Skye Bioscience CFO Granted Stock Options

Skye Bioscience's Chief Financial Officer, Kaitlyn Arsenault, was granted 125,000 stock options with an exercise price of $0.82, vesting over four years.

Summary

• Kaitlyn Arsenault, Chief Financial Officer of Skye Bioscience, Inc. (SKYE), was granted 125,000 stock options.
• The stock options have an exercise price of $0.82 per share.
• The earliest transaction date for these options is February 6, 2026.
• The options will vest in equal monthly installments over a four-year period, commencing on January 19, 2026.
• The expiration date for these stock options is February 6, 2036.
• Following this transaction, Kaitlyn Arsenault beneficially owns 125,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive compensation practice that aligns management incentives with shareholder value creation, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing performance and value creation.
• Stock options are a common form of executive compensation, designed to attract and retain key talent.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of Skye Bioscience's common stock exceeding the exercise price of $0.82.
• If the company's stock price does not perform well, the options may not become 'in-the-money' or may lose value.
• The options are subject to a four-year vesting schedule, meaning the full benefit is not immediate and is contingent on continued employment and performance.

Future Outlook

The stock option grant provides a long-term incentive for the Chief Financial Officer, with vesting over four years, suggesting a commitment to future performance and alignment with the company's strategic goals.

Industry Context

Stock options are a widely adopted component of executive compensation packages across various industries, particularly in biotechnology and emerging growth companies like Skye Bioscience. StockSavvy.ai notes that this practice aims to motivate executives by linking their personal wealth directly to the company's stock performance, a common strategy for talent retention and alignment with shareholder interests.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures seen at companies like Biogen Inc. or Moderna, Inc., which frequently utilize equity incentives to attract and retain top-tier executive talent.
• The four-year vesting schedule is typical for executive equity grants, aligning with industry benchmarks for long-term incentive plans designed to foster sustained performance and commitment.
• The exercise price of $0.82, being the market price at the time of grant, is a common feature of 'at-the-money' options, consistent with best practices in executive compensation to ensure future value creation is tied to stock appreciation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized management, balanced against potential future dilution from option exercise.
• Chief Financial Officer: Receives a significant equity incentive, aligning personal financial interests with company performance.

Next Steps

• The stock options will begin vesting in equal monthly installments starting January 19, 2026, over a four-year period.

Key Dates

Keywords

Skye Bioscience, SKYE, Form 4, stock options, executive compensation, insider transaction, Kaitlyn Arsenault, CFO, equity incentive